

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

**Claims 1. – 18. (Canceled)**

**Claim 19. (Canceled)**

**Claim 20. (Canceled)**

**Claim 21. (Currently Amended)** A conjugate according to claim 4420 wherein the molecule capable of inducing blood coagulation and blood vessel occlusion is a photoactive molecule.

**Claim 22. (Previously presented)** A conjugate according to claim 21 wherein the photoactive molecule is a photosensitizer.

**Claim 23. (Previously presented)** A conjugate according to claim 22 wherein the photosensitizer absorbs at a wavelength above 600 nm.

**Claim 24. (Currently Amended)** A conjugate according to claim 22 wherein the photosensitizer is a derivative of tin (IV) chlorinechlorine e6.

**Claim 25. (Currently Amended)** A conjugate according to claim 4420 wherein the molecule capable of inducing blood coagulation and blood vessel occlusion is a radionuclide.

**Claim 26. (Previously Presented)** A conjugate according to claim 25 wherein the radionuclide is a  $\beta$ - emitting radionuclide.

**Claim 27. (Canceled)**

**Claim 28. (Canceled)**

**Claim 29. (Currently Amended)** A method for the treatment of an angiogenesis-related pathology in a patient comprising administering a conjugate according to claim 4420.

**Claim 30. (Previously Presented)** A method for the treatment of an angiogenesis-related pathology in a patient comprising administering a conjugate according to claim 22 by injections, followed by irradiating said patient.

**Claim 31. (Previously Presented)** A method according to claim 30 wherein the angiogenesis-related pathology treated is caused by or associated with ocular angiogenesis.

**Claim 32. (Previously Presented)** A method for the treatment of an angiogenesis-related pathology comprising administering a radionuclide-containing conjugate according to claim 25 by injection.

**Claim 33. (Previously Presented)** A method according to claim 32 wherein the radionuclide is astatine-211.

**Claim 34. (Canceled)**

**Claim 35. (Canceled)**

**Claim 36. (Canceled)**

**Claim 37. (Previously Presented)** A conjugate of claim 4436 wherein the antibody is radiolabeled.

**Claim 38. (Previously Presented)** A conjugate of claim 37 wherein the antibody is radioiodinated.

**Claim 39. (Canceled)**

**Claim 40. (Currently Amended)** A conjugate of claim 4439 wherein the antibody is produced recombinantly.

**Claim 41. (Currently Amended)** A conjugate of claim 4436 wherein the ED-B domain of fibronectin is a human ED-B domain.

**Claim 42. (Canceled)**

**Claim 43. (Previously Presented)** A diagnostic kit comprising a conjugate of claim 37 and one or more reagents for detecting angiogenesis.

**Claim 44. (Currently Amended)** A conjugate comprising (a) an scFv antibody with specific, high affinity for the ED-B domain of fibronectin ~~which has having VH, VL and linker domains with the amino acid sequences sequences encoded by, respectively, by the VH, VL, and linker DNA of the DNA insert of ATCC deposit no. PTA-9529~~ and (b) a molecule capable of inducing blood coagulation and blood vessel occlusion.

**Claim 45. (Canceled)**